Finance

Lists
Why is CRSP up 3.57%?
Dive Deeper
CRSP:NASDAQ
Crispr Therapeutics AG
US$51.78
+3.57%
(+1.78) 1D
US$51.23
-1.05% (-0.55)
After hours
Closed: ኖቬም 4, 4:00:00 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRSP...
Open
US$51.48
High
US$52.50
Low
US$50.19
Mkt. cap
5.02 ቢ
Avg. vol.
1.47 ሚ
Volume
1.39 ሚ
52-wk high
US$63.45
52-wk low
US$44.12
EPS
-US$4.75
Beta
1.49
Shares outstanding
97.00 ሚ
No. of employees
393
Open
US$51.48
High
US$52.50
Low
US$50.19
Mkt. cap
5.02 ቢ
Avg. vol.
1.47 ሚ
Volume
1.39 ሚ
52-wk high
US$63.45
52-wk low
US$44.12
EPS
-US$4.75
Beta
1.49
Shares outstanding
97.00 ሚ
No. of employees
393
News stories
From web sources and news partners
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, ስዊዘርላንድ
SectorBiotechnology
Industry-
Analyst ratings
Based on 14 analysts giving stock ratings to CRSP in the past 3 months
Buy
Buy
8
Hold
6
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for CRSP in the last 3 months.
Highest
Current US$51.78
US$110.00 (+112.46%)
Average
US$70.83 (+36.80%)
Lowest
US$45.00 (-13.09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Buy
Reiterated
US$80.00
+54.5%
11/04/2026
Yigal Nochomovitz
Citi
Buy
Maintained
US$90.00
+73.8%
11/04/2026
Yanan Zhu
Wells Fargo
Hold
Reiterated
US$70.00
+35.2%
11/04/2026
Luca Issi
RBC Capital
Hold
Maintained
US$50.00
-3.4%
11/03/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
US$80.00
+54.5%
11/04/2026
Joon Lee
UBS
Hold
Maintained
US$52.00
+0.4%
11/03/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
US$110.00
+112.5%
11/03/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
-
-
11/03/2026
Tyler Van Buren
TD Cowen
Hold
Maintained
US$45.00
-13.1%
10/21/2026
Gil Blum
Needham
Buy
Maintained
US$82.00
+58.4%
10/05/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
US$76.00
+46.8%
08/31/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/28/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
US$60.00
+15.9%
08/28/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
US$55.00
+6.2%
08/10/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
US$55.00
+6.2%
08/06/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
US$60.00
+15.9%
08/04/2026
Silvan Turkcan
Citizens JMP
Buy
Maintained
US$80.00
+54.5%
07/22/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
US$85.00
+64.2%
06/10/2026
William Pickering
Bernstein
Hold
Reiterated
US$56.00
+8.2%
05/13/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
US$76.00
+46.8%
05/04/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
US$80.00
+54.5%
01/30/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
889.00 ሺ
864.00 ሺ
1.46 ሚ
10.18 ሚ
Cost of goods sold
116.02 ሚ
137.23 ሚ
114.52 ሚ
107.42 ሚ
Cost of revenue
116.02 ሚ
137.23 ሚ
114.52 ሚ
107.42 ሚ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.93 ሚ
18.40 ሚ
17.18 ሚ
17.55 ሚ
Operating expense
16.93 ሚ
18.40 ሚ
17.18 ሚ
17.55 ሚ
Total operating expenses
132.95 ሚ
155.63 ሚ
131.71 ሚ
124.98 ሚ
Operating income
-132.06 ሚ
-154.76 ሚ
-130.25 ሚ
-114.80 ሚ
Other non operating income
26.24 ሚ
24.76 ሚ
8.16 ሚ
27.08 ሚ
EBT including unusual items
-105.82 ሚ
-130.00 ሚ
-122.09 ሚ
-90.19 ሚ
EBT excluding unusual items
-105.82 ሚ
-130.00 ሚ
-122.09 ሚ
-87.72 ሚ
Income tax expense
619.00 ሺ
614.00 ሺ
839.00 ሺ
960.00 ሺ
Effective tax rate
-0.58%
-0.47%
-0.69%
-1.06%
Other operating expenses
-
-
-
-
Net income
-106.44 ሚ
-130.61 ሚ
-122.93 ሚ
-91.15 ሚ
Net profit margin
-11,973.12%
-15,117.25%
-8,431.48%
-895.33%
Earnings per share
-1.17
-1.37
-1.28
-0.94
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-127.63 ሚ
-149.10 ሚ
-125.93 ሚ
-110.52 ሚ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች